The GSS Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Jurkat human T lymphocyte cell line, designed to disrupt the glutathione synthetase (GSS) gene. This product offers a heterogeneous pool of cells with targeted gene disruption, enabling studies of GSS loss-of-function without clonal selection bias. The polyclonal format is particularly suited for bulk population analyses of glutathione metabolism and redox-dependent phenotypes, providing an efficient model for functional investigations in a T-cell context.
Jurkat cells, originally isolated from the peripheral blood of a 14-year-old male with acute T-cell leukemia, serve as a classic model for T lymphocyte signaling, leukemia biology, and apoptosis. They retain key features of T cells, including surface marker expression and intact signal transduction pathways, making them a relevant host for exploring gene functions that impact immune cell physiology. The knockout of GSS in this background thus enables examination of glutathione’s role specifically in T-cell malignancy and stress responses.
Glutathione synthetase (GSS) catalyzes the ATP-dependent condensation of gamma-glutamylcysteine and glycine to produce glutathione (GSH), the predominant intracellular antioxidant. GSS functions downstream of glutamate-cysteine ligase (GCL) and is transcriptionally upregulated by NFE2L2 (Nrf2) and AP-1 under oxidative stress. The synthesized GSH participates in ROS detoxification via glutathione peroxidases (GPX) and is regenerated by glutathione reductase (GSR), thereby maintaining cellular redox equilibrium. Disruption of GSS abrogates glutathione production, leading to diminished antioxidant capacity and accumulation of reactive oxygen species, which in turn triggers redox-sensitive signaling cascades affecting cell survival and proliferation.
In Jurkat T cells, the loss of GSS provides a robust system to interrogate the dependence of leukemia cells on glutathione homeostasis. Given the elevated oxidative metabolism in many cancers, including T-cell leukemias, this knockout reveals vulnerabilities in redox control that may be exploited therapeutically. The polyclonal population reflects the heterogeneity of editing outcomes, allowing researchers to observe variable responses to oxidative challenges and drug treatments, which can better model the complexity of tumor biology. This model is valuable for studying mechanisms of drug resistance where GSH-mediated detoxification plays a critical role.
Typical applications include biochemical quantification of intracellular glutathione levels, real-time monitoring of ROS using fluorescent probes, and cell viability assays under oxidative stress induced by hydrogen peroxide or chemotherapeutics. Researchers can validate GSS disruption via western blotting or RT-qPCR and assess apoptosis by Annexin V flow cytometry. The cells also enable high-throughput screening of small molecules targeting glutathione biosynthesis or potentiating oxidative stress. Furthermore, this tool supports investigations into the Nrf2?CGSS?CGSH axis and its contribution to redox adaptation in T-cell leukemia. For further information or technical support, please contact Ascent Research.
